<DOC>
	<DOCNO>NCT01625494</DOCNO>
	<brief_summary>Primary Objective : - To assess proportion patient control Office Blood Pressure Measurements ( OBPM ) , define Systolic blood pressure &lt; 140 mmHg Diastolic blood pressure &lt; 90mmHg , end study Secondary Objectives : - To examine time antihypertensive effect 4 dos fix combination therapy irbesartan/amlodipine OBPM ( SBP ( systolic blood pressure ) DBP ( diastolic blood pressure ) - To examine proportion patient control OBPM ( systolic BP &lt; 140 mm Hg diastolic BP &lt; 90 mmHg ) different dose group time - To determine incidence severity adverse event .</brief_summary>
	<brief_title>Study Efficacy Safety Irbesartan/Amlodipine 4 Fixed Combination Therapy Hypertensive Patients Uncontrolled Irbesartan Amlodipine Monotherapy</brief_title>
	<detailed_description>16 week - V1 ( week 0 ) : Inclusion visit . - V2 ( Week 4 ) : Irbesartan/amlodipine 150/5 mg fix combination visit - V3 ( Week 8 ) : 1st dose escalation patient OBPM control ( SBP ≥ 140 mmHg DBP ≥ 90mmHg , - V4 ( Week 12 ) : 2nd Dose escalation visit patient OBPM control ( SBP ≥ 140 mmHg DBP ≥ 90mmHg - V5 ( Week 16 ) : End study visit</detailed_description>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : Men woman ≥18 year old Established essential hypertension Treated irbesartan 150 mg amlodipine 5 mg monotherapy least 2 week With uncontrolled systolic BP ( blood pressure ) define ≥140 mm Hg assess OBPM ( office blood pressure measurement ) Signed write informed consent obtain prior inclusion study Exclusion criterion : Mean systolic BP ≥180 mm Hg and/or mean diastolic BP ≥110 mm Hg OBPM Visit 1 Known suspect cause secondary hypertension Patients bilateral artery stenosis , renal artery stenosis solitary kidney , renal transplant one functioning kidney Known contraindication hypersensitivity either amlodipine irbesartan combination History angioedema related administration angiotensin II receptor antagonist combination drug use Severe hepatic impairment ( Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &gt; 5 time upper normal limit ( ULN ) history hepatic encephalopathy , esophageal varix portocaval shunt ) Severe renal impairment ( glomerular filtration rate &lt; 30 ml/min ) Concomitant use antihypertensive treatment except Irbesartan Amlodipine Administration investigational drug within 30 day inclusion Presence condition would restrict limit patient participation duration study Pregnant breast feed woman Women childbearing potential unable unwilling use acceptable method avoid pregnancy entire study period Patient investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>